Reuters logo
BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone
September 13, 2017 / 9:38 PM / a month ago

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

Sept 13 (Reuters) - Reata Pharmaceuticals Inc

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

* Reata Pharmaceuticals Inc - ‍FDA granted orphan designation to Omaveloxolone for treatment of stage IIb through IV malignant melanoma​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below